NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis → Prepare for a recession unlike any other (From American Hartford Gold Group) (Ad) Free JSPR Stock Alerts $22.03 -0.08 (-0.36%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$21.40▼$22.5550-Day Range$17.48▼$30.0052-Week Range$4.00▼$31.01Volume44,701 shsAverage Volume76,015 shsMarket Capitalization$331.77 millionP/E RatioN/ADividend YieldN/APrice Target$64.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Jasper Therapeutics alerts: Email Address Jasper Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside191.3% Upside$64.17 Price TargetShort InterestHealthy3.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$4.53 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.00) to ($4.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 starsMedical Sector534th out of 907 stocksBiological Products, Except Diagnostic Industry87th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingJasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.84% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 38.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JSPR. Previous Next 2.7 News and Social Media Coverage News SentimentJasper Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Jasper Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows6 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have bought 18,947.32% more of their company's stock than they have sold. Specifically, they have bought $4,532,500.00 in company stock and sold $23,796.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($5.00) to ($4.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Jasper Therapeutics Stock (NASDAQ:JSPR)Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.Read More JSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JSPR Stock News HeadlinesApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment MarketApril 2, 2024 | globenewswire.comJasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 28, 2024 | msn.comRBC starts Jasper Therapeutics at outperform, cites market opportunityMarch 21, 2024 | globenewswire.comJasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria TreatmentMarch 20, 2024 | finance.yahoo.comJasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26%March 19, 2024 | globenewswire.comJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible UrticariaApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 16, 2024 | finance.yahoo.comJSPR Jul 2024 40.000 callMarch 15, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 15, 2024 | globenewswire.comNew Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 14, 2024 | msn.comEntrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85MMarch 11, 2024 | finance.yahoo.comJSPR Oct 2024 30.000 callMarch 10, 2024 | finance.yahoo.comJSPR Oct 2024 17.500 callMarch 10, 2024 | finance.yahoo.comJSPR Apr 2024 35.000 callMarch 6, 2024 | finance.yahoo.comJSPR Mar 2024 22.500 putMarch 6, 2024 | investorplace.comJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023March 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria TreatmentMarch 4, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comJasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 3, 2024 | finance.yahoo.comJSPR Mar 2024 15.000 putFebruary 27, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)February 27, 2024 | markets.businessinsider.comBuy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria TreatmentFebruary 26, 2024 | globenewswire.comJasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare ConferenceFebruary 23, 2024 | globenewswire.comJasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingFebruary 23, 2024 | finance.yahoo.comJSPR Mar 2024 20.000 callSee More Headlines Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:JSPR CUSIPN/A CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Target$64.17 High Stock Price Target$80.00 Low Stock Price Target$40.00 Potential Upside/Downside+191.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($6.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.21% Return on Assets-55.07% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.03 per share Price / Book3.13Miscellaneous Outstanding Shares15,060,000Free Float14,477,000Market Cap$331.77 million OptionableOptionable Beta2.22 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Ronald A. Martell (Age 62)President, CEO & Director Comp: $892.45kDr. Judith Anne Shizuru M.D. (Age 68)Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director Comp: $291.25kMr. Jeetinder Singh Mahal M.B.A. (Age 52)Chief Operating Officer Comp: $579.46kMr. Herbert C. Cross (Age 52)CFO & Corporate Secretary Dr. Luca Di Noto Ph.D.Senior Vice President of Technical OperationsMr. David Ku M.D.Vice President of Corporate Development, Portfolio Strategy & ManagementMr. Matthew FordVice President of Human ResourcesDr. Wendy Pang M.D.Ph.D., Senior Vice President of Research & Translational MedicineDr. Edwin Jonathan Tucker M.D. (Age 52)Chief Medical Officer Ms. Patricia CarlosSenior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsAura BiosciencesNASDAQ:AURASolid BiosciencesNASDAQ:SLDBCaribou BiosciencesNASDAQ:CRBUDocGoNASDAQ:DCGOAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 500,000 shares on 3/18/2024Ownership: 31.720%Jeetinder Singh MahalSold 900 sharesTotal: $23,796.00 ($26.44/share)Opaleye Management Inc.Bought 3,985,340 shares on 2/15/2024Ownership: 35.717%Velan Capital Investment ManagBought 350,000 shares on 2/8/2024Total: $4.53 M ($12.95/share)Monaco Asset Management SAMBought 249,563 shares on 2/7/2024Ownership: 2.236%View All Insider TransactionsView All Institutional Transactions JSPR Stock Analysis - Frequently Asked Questions Should I buy or sell Jasper Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares. View JSPR analyst ratings or view top-rated stocks. What is Jasper Therapeutics' stock price target for 2024? 8 equities research analysts have issued 12 month price targets for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $80.00. On average, they anticipate the company's stock price to reach $64.17 in the next year. This suggests a possible upside of 191.3% from the stock's current price. View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts. How have JSPR shares performed in 2024? Jasper Therapeutics' stock was trading at $7.89 at the beginning of 2024. Since then, JSPR shares have increased by 179.2% and is now trading at $22.03. View the best growth stocks for 2024 here. When is Jasper Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our JSPR earnings forecast. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) posted its quarterly earnings results on Monday, March, 4th. The company reported ($1.50) EPS for the quarter, beating analysts' consensus estimates of ($1.65) by $0.15. When did Jasper Therapeutics' stock split? Jasper Therapeutics's stock reverse split on Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JSPR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
